Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics是一家临床阶段的公司，正在开发一类新型心血管疾病基因药物，今天宣布，于2024年11月29日，公司根据纳斯达克规则5635(c)(4)向一名新员工授予股权奖励，作为该新员工进入公司就职的重要诱因，依据公司的2024年诱因股票激励计划。
The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee's continued service with the company on each such vesting date.
该员工获得了共计5,330个受限制的股票单位（RSUs）。这些RSUs将在2025年1月1日的头四个周年纪念日以相等的年度分期解禁，前提是该员工在每个解禁日期继续为公司提供服务。
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company's lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit .
关于Verve Therapeutics
Verve Therapeutics，Inc.(纳斯达克代码：VERV)是一家临床阶段的遗传药品公司，开创了一种新的心血管疾病护理方式，可能将治疗从慢性管理转变为单次基因编辑药品。公司的主要项目VERVE-101、VERVE-102和VERVE-201针对已被广泛验证为低密度脂蛋白胆固醇（LDL-C）降低的靶点基因，这是动脉粥样硬化性心血管疾病（ASCVD）的根本原因。VERVE-101和VERVE-102旨在永久关闭肝脏中的PCSK9基因，并首先开发用于杂合子家族性高胆固醇血症（HeFH），最终用于治疗继续受高LDL-C水平影响的已确诊ASCVD患者。VERVE-201旨在永久关闭一种受体基因，该基因的降解被认为是促进冠状动脉血管单位深度和体积增加的关键步骤，因此是一种可能的靶切点，因为它可能降低心血管病发作的风险。
Verve Therapeutics，Inc.（纳斯达克：VERV）是一家临床阶段的公司，正在开发一类新型心血管疾病基因药物，有潜力将治疗从慢性管理转变为单疗程基因编辑药物。该公司的主要项目-VERVE-101、VERVE-102和VERVE-201-瞄准已被广泛验证为降低低密度脂蛋白胆固醇（LDL-C）的靶点基因，LDL-C是动脉粥样硬化心血管疾病（ASCVD）的根本原因。VERVE-101和VERVE-102旨在永久关闭肝脏中的PCSK9基因，最初用于杂合子家族性高胆固醇血症（HeFH），最终用于治疗已受高LDL-C水平影响的已确诊ASCVD患者。VERVE-201旨在永久关闭肝脏中的ANGPTL3基因，最初用于难治性高胆固醇血症，即患者尽管接受了最大可耐受的标准护理疗法治疗，仍然具有高LDL-C水平，以及纯合子家族性高胆固醇血症（HoFH）。欲了解更多信息，请访问。
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
投资者联系人
詹·罗宾逊
Verve Therapeutics，Inc。
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
媒体联系
阿什莉·科西科夫斯基
1AB
ashlea@1abmedia.com
译文内容由第三方软件翻译。
